AbbVie Inc (ABBV.PH)

ABBV.PH on Philadelphia Stock Exchange

52.22USD
11 Feb 2016
Change (% chg)

$-0.50 (-0.95%)
Prev Close
$52.72
Open
$52.60
Day's High
$52.77
Day's Low
$51.83
Volume
97,405
Avg. Vol
92,084
52-wk High
$71.59
52-wk Low
$45.47

ABBV.PH

Chart for ABBV.PH

About

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease; hepatitis C (HCV);... (more)

Overall

Beta: --
Market Cap(Mil.): $85,301.09
Shares Outstanding(Mil.): 1,634.75
Dividend: 0.57
Yield (%): 4.37

Financials

  ABBV.PH Industry Sector
P/E (TTM): 16.61 31.28 37.85
EPS (TTM): 3.14 -- --
ROI: -- 14.74 14.09
ROE: -- 15.31 14.83
Search Stocks

FDA staff backs biosimilar to Remicade; J&J and AbbVie fall

(This version of the story corrects that Zarzio is a version of Amgen's Neupogen, not Neulasta, and that Zarzio was priced at a discount to Neupogen, not Neulasta, in final two paragraphs)

09 Feb 2016

CORRECTED-UPDATE 4-FDA staff backs biosimilar to Remicade; J&J and AbbVie fall

Feb 5 U.S. Food and Drug Administration staff members on Friday said Celltrion Inc's biosimilar form of Johnson & Johnson's Remicade arthritis drug appeared "highly similar" to the widely used branded product.

09 Feb 2016

AbbVie shares fall on sales outlooks for Humira and Viekira Pak

AbbVie Inc on Friday predicted slower growth this year in overseas sales of its blockbuster Humira arthritis drug and cut sales estimate for its new Viekira Pak treatment for hepatitis C, sending shares 4 percent lower.

29 Jan 2016

UPDATE 3-AbbVie shares fall on sales outlooks for Humira and Viekira Pak

Jan 29 AbbVie Inc on Friday predicted slower growth this year in overseas sales of its blockbuster Humira arthritis drug and cut sales estimate for its new Viekira Pak treatment for hepatitis C, sending shares 4 percent lower.

29 Jan 2016

BRIEF-AbbVie expects $2 bln sales for Viekira Pak in 2016

* Abbvie says has been diffifult to forecast sales of viekira pak, believes $2 billion estimate for 2016 is very reliable

29 Jan 2016

BRIEF-Abbvie expects 2016 mid-single digit growth for Humira outside U.S.

* Says expects mid-single digit percentage sales growth for humira this year in international markets Source text for Eikon: Further company coverage: (Reporting by Ransdell Pierson)

29 Jan 2016

Drugmaker AbbVie reports higher quarterly revenue

Jan 29 Drugmaker AbbVie Inc reported a 17.4 percent jump in quarterly revenue, driven by higher sales of its arthritis drug, Humira.

29 Jan 2016

FDA approves Merck's new hepatitis C pill

U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.

28 Jan 2016

UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill

Jan 28 U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.

28 Jan 2016

U.S. FDA approves Merck's new hepatitis C pill

Jan 28 U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc.

28 Jan 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.70 -0.03
Pfizer Inc. (PFE.N) $29.13 -0.36
Novartis AG (NOVN.VX) CHF70.45 +0.90
Merck & Co., Inc. (MRK.N) $48.85 -0.68
Roche Holding Ltd. (ROG.VX) CHF242.50 +1.80
Abbott Laboratories (ABT.N) $36.34 -0.87
Eli Lilly and Co (LLY.N) $71.42 -1.65
Sanofi SA (SASY.PA) €67.83 +0.56

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks